Skip to main content
Haemato AG logo

Haemato AG — Investor Relations & Filings

Ticker · HAEK ISIN · DE000A289VV1 LEI · 529900Q3CGRYVCW7E340 F Wholesale and retail trade
Open in API
Filings indexed 188 across all filing types
Latest filing 2020-06-08 Annual Report
Country DE Germany
Listing F HAEK

About Haemato AG

https://haemato.de/en/start.html

Haemato AG is a pharmaceutical company focused on the specialty pharma market, concentrating on treatments for chronic diseases and high-priced therapies. The company's business activities include the development, acquisition, licensing, and distribution of a product portfolio that comprises innovative patent-protected medicines, biosimilars, and generics. The portfolio also extends to narcotics, including cannabis products, as well as over-the-counter (OTC) products and special cosmetics. Haemato AG's primary therapeutic areas of focus are HIV/AIDS, neurology, oncology, rheumatology, and ophthalmology.

Recent filings

Filing Released Lang Actions
Annual financial statements 2019
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2019' and contains comprehensive financial statements, including the consolidated balance sheet, statement of comprehensive income, cash flow statement, and detailed notes to the financial statements. It covers the full fiscal year and provides a management report, supervisory board report, and auditor's report, which are standard components of a formal Annual Report (10-K equivalent). FY 2019
2020-06-08 German
HAEMATO AG: Annual General Meeting postponement
AGM Information Classification · 98% confidence The document explicitly discusses the postponement of the 'Annual General Meeting' (AGM) originally scheduled for July 8, 2020. The key phrase is 'HAEMATO AG: Annual General Meeting postponement' and the content revolves around rescheduling this specific corporate event. This directly aligns with the definition of 'AGM Information' (Code: AGM-R), which covers presentations and materials shared during the AGM. Although this is an announcement about the AGM rather than the meeting materials themselves, the postponement notice is intrinsically linked to the AGM process and is a specific type of corporate action related to it, making AGM-R the most appropriate fit over a general regulatory filing (RNS). The document length is short (2881 chars), but the content is highly specific to the AGM event itself.
2020-05-27 English
HAEMATO AG: Results Q1 2020
Earnings Release Classification · 100% confidence The document is titled "HAEMATO AG: Results Q1 2020" and provides key financial figures (sales, EBIT, profit) for the first quarter of 2020. This strongly suggests an earnings announcement. It is short, uses the DGAP news service format, and explicitly states the results, which aligns with the definition of an Earnings Release (ER). Although it mentions the Annual Report 2019 was published previously, the core content here is the Q1 2020 performance summary. It is not a comprehensive Interim Report (IR) as it only provides highlights and is structured as a news release, not a full financial statement. Q1 2020
2020-05-18 English
HAEMATO AG: appropriation of profits
Notice of Dividend Amount Classification · 99% confidence The document is an 'Ad-hoc' announcement dated April 21, 2020, concerning the 'appropriation of profits'. Specifically, it states that the Management Board's proposal for the appropriation of retained earnings for the 2019 financial year will be presented to the Annual General Meeting (AGM) scheduled for July 8, 2020. This announcement is about the proposal related to the distribution of profits, which directly relates to dividends or retained earnings decisions typically finalized at an AGM. Since the document explicitly mentions the proposal for profit appropriation to be discussed at the AGM, and the key word is 'Dividend', the most fitting category is 'Notice of Dividend Amount' (DIV) or potentially 'AGM Information' (AGM-R). However, the core subject is the proposal regarding retained earnings/profit appropriation, which is a precursor to a dividend declaration or retention decision. Given the options, 'DIV' covers the outcome of profit appropriation (dividend payment or retention). If the proposal was to pay a dividend, DIV would be correct. If it was just about the AGM agenda, AGM-R might fit. Since the text focuses on the proposal for profit appropriation (retained earnings carried forward), which is a direct financial decision impacting shareholders, DIV is a strong candidate, but the document is an announcement *about* the proposal to be made at the AGM, not the final dividend notice itself. Let's re-evaluate based on the definitions. It is not a final dividend notice (DIV), nor is it the AGM material itself (AGM-R). It is an inside information disclosure (MAR Article 17) about a proposal regarding profits. This type of announcement, dealing with the outcome of the financial year's results concerning shareholder returns, often falls under DIV or ER/IR. Since it's about profit appropriation, DIV is the closest fit among the distribution-related codes. However, because it is an announcement *before* the AGM where the final decision is made, and it's a regulatory disclosure (Ad-hoc/MAR), it could also be considered a general Regulatory Filing (RNS). Given the specific nature of the content (profit appropriation proposal), DIV is more specific than RNS. I will classify it as DIV because profit appropriation directly dictates dividend policy or retention.
2020-04-21 English
HAEMATO AG: Preliminary IFRS results 2019
Earnings Release Classification · 100% confidence The document is titled "HAEMATO AG: Preliminary IFRS results 2019" and explicitly states preliminary consolidated sales, EBIT, and net profit figures for the fiscal year 2019. It provides key financial highlights immediately following the reporting period, which is characteristic of an Earnings Release (ER). It is not a comprehensive annual report (10-K) or a detailed interim report (IR), but rather the initial announcement of the results. The document is short and focuses on summarizing the preliminary figures, fitting the definition of an Earnings Release. FY 2019
2020-03-25 English
HAEMATO AG: IFRS Third-Quarter 2019 Results
Earnings Release Classification · 100% confidence The document is titled "HAEMATO AG: IFRS Third-Quarter 2019 Results" and provides key financial figures (revenues, EBITDA) for the nine-month period ending September 30, 2019, along with specific Q3 2019 performance details. This content structure—summarizing results for a period shorter than a full year (nine months)—is characteristic of an Interim/Quarterly Report. Although it is presented as a news release (DGAP-News), the core content is the financial summary itself, not just an announcement that a report is forthcoming (which would suggest RPA or RNS). It is more detailed than a typical Earnings Release (ER) which usually focuses only on highlights, making 'IR' (Interim/Quarterly Report) the most appropriate classification for the substance of the filing. 9M 2019
2019-11-22 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.